The mission of the Children's Oncology Group (COG) is to cure and prevent childhood and adolescent cancer through scientific discovery and compassionate care. Our vision is to eliminate the personal, familial, and societal burden of cancer in children and adolescents by conducting, treatment trials, etiologic and prevention studies to lessen the burden of treatment-related sequelae and improve survivorship. First funded in 2002, this application is for COG to continue to serve as a Treatment and Cancer Prevention and Control Community Clinical Oncology Program (CCOP) Research Base. COG is the largest childhood cancer research organization in the world encompassing 231 pediatric cancer programs including 27 affiliated with CCOPs/Minority-Based CCOPs. The COG CCOP Research Base utilizes the organization and facilities of the COG to provide community pediatric cancer treatment centers access to treatment, cancer biology, cancer prevention and control protocols. Involvement of community-based pediatricians in the research mission of the COG is a high priority. Our performance in the current grant period has been strong evidenced by: a striking year-to-year increase in accrual to cancer prevention and control studies; steady increases in the number of available protocols; enhanced interactions between COG Disease, Discipline and other scientific committees resulting in more integrated cancer control protocol concepts; and active participation of CCOP investigators in COG operations. Cancer prevention and control accrual rose from 91 in 3/1/03-2/29/04 to 377 in 3/1/04-2/28/05 to 1,195 for the 3/1/05-2/1/06 period. In the 2004-2005 period, COG had 10 open cancer control protocols, this increased to 18 protocols in 2005-2006. Cancer prevention and control research is coordinated by the COG Cancer Control Committee which has identified the following priority areas: permanent treatment-related disabilities; nutrition, obesity/energy balance; acute symptoms/complications of treatment; end-of life/palliative care; and patient-reported outcomes. The CCOP Subcommittee promotes the design and conduct of pediatric cancer control research as well as supports CCOP member institutions and investigators in both local and Group-wide affairs. CCOPs provide an important mechanism to evaluate advanced treatments administered in community settings and broaden the population-base for protocol participation. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA095861-06
Application #
7282270
Study Section
Special Emphasis Panel (ZCA1-SRRB-3 (J1))
Program Officer
O'Mara, Ann M
Project Start
2002-09-20
Project End
2012-05-31
Budget Start
2007-08-22
Budget End
2008-05-31
Support Year
6
Fiscal Year
2007
Total Cost
$1,567,888
Indirect Cost
Name
National Childhood Cancer Foundation
Department
Type
DUNS #
624124301
City
Arcadia
State
CA
Country
United States
Zip Code
91006
Dupuis, L Lee; Kelly, Kara M; Krischer, Jeffrey P et al. (2018) Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blinded, randomized controlled trial. Cancer 124:1188-1196
Zheng, Daniel J; Lu, Xiaomin; Schore, Reuven J et al. (2018) Longitudinal analysis of quality-of-life outcomes in children during treatment for acute lymphoblastic leukemia: A report from the Children's Oncology Group AALL0932 trial. Cancer 124:571-579
Alexander, Sarah; Fisher, Brian T; Gaur, Aditya H et al. (2018) Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial. JAMA 320:995-1004
Landier, Wendy; Chen, Yanjun; Hageman, Lindsey et al. (2017) Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. Blood 129:1919-1926
Knight, Kristin R; Chen, Lu; Freyer, David et al. (2017) Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. J Clin Oncol 35:440-445
Haase, Joan E; Kintner, Eileen K; Robb, Sheri L et al. (2017) The Resilience in Illness Model Part 2: Confirmatory Evaluation in Adolescents and Young Adults With Cancer. Cancer Nurs 40:454-463
Freyer, David R; Chen, Lu; Krailo, Mark D et al. (2017) Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18:63-74
Viola, Adrienne; Balsamo, Lyn; Neglia, Joseph P et al. (2017) The Behavior Rating Inventory of Executive Function (BRIEF) to Identify Pediatric Acute Lymphoblastic Leukemia (ALL) Survivors At Risk for Neurocognitive Impairment. J Pediatr Hematol Oncol 39:174-178
Landier, Wendy; Hageman, Lindsey; Chen, Yanjun et al. (2017) Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. J Clin Oncol 35:1730-1736
Roth, Michael E; O'Mara, Ann M; Seibel, Nita L et al. (2016) Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program. J Oncol Pract 12:e388-95

Showing the most recent 10 out of 66 publications